Monopar Therapeutics, a biopharmaceutical company listed on the NASDAQ under the symbol MNPR, has announced the pricing of its underwritten registered offering, which will raise approximately...
Monopar Therapeutics has successfully priced a significant underwritten registered offering, raising a total of $135 million. The offering, announced on October 3, 2023, includes the sale...